Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 11-20 of 41 (Search time: 0.003 seconds).
previous
1
2
3
4
5
next
Item hits:
Preview
Issue Date
Title
Author(s)
2014
Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells
Nievergall, E.
;
Ramshaw, H.
;
Yong, A.
;
Biondo, M.
;
Busfield, S.
;
Vairo, G.
;
Lopez, A.
;
Hughes, T.
;
White, D.
;
Hiwase, D.
2018
ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
Eadie, L.
;
Dang, P.
;
Goyne, J.
;
Hughes, T.
;
White, D.
;
Maga, G.
2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Ross, D.
;
Branford, S.
;
Seymour, J.
;
Schwarer, A.
;
Arthur, C.
;
Yeung, D.
;
Dang, P.
;
Goyne, J.
;
Slader, C.
;
Filshie, R.
;
Mills, A.
;
Vaz de Melo, J.
;
White, D.
;
Grigg, A.
;
Hughes, T.
2013
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
Angelini, S.
;
Soverini, S.
;
Ravegnini, G.
;
Barnett, M.
;
Turrini, E.
;
Thornquist, M.
;
Pane, F.
;
Hughes, T.
;
White, D.
;
Radich, J.
;
Kim, D.
;
Saglio, G.
;
Cilloni, D.
;
Iacobucci, I.
;
Perini, G.
;
Woodman, R.
;
Cantelli-Forti, G.
;
Baccarani, M.
;
Hrelia, P.
;
Martinelli, G.
2016
BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia
Latham, S.
;
Bartley, P.
;
Budgen, B.
;
Ross, D.
;
Hughes, E.
;
Branford, S.
;
White, D.
;
Hughes, T.
;
Morley, A.
2013
Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells
White, D.
;
Eadie, L.
;
Saunders, V.
;
Hiwase, D.
;
Hughes, T.
2010
Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy
Hiwase, D.
;
White, D.
;
Zrim, S.
;
Saunders, V.
;
Vaz de Melo, J.
;
Hughes, T.
2010
Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity
Engler, J.
;
Frede, A.
;
Saunders, V.
;
Zannettino, A.
;
Hughes, T.
;
White, D.
2013
NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis
Watkins, D.
;
Hughes, T.
;
White, D.
;
D'Andrea, R.
2011
OCT-1 as a determinant of response to antileukemic treatment
Engler, J.
;
Hughes, T.
;
White, D.
Discover
Author
12
Saunders, V.
9
Hiwase, D.
9
Yeung, D.
8
Kok, C.
7
Dang, P.
6
Branford, S.
6
Eadie, L.
6
Frede, A.
5
Engler, J.
5
Leclercq, T.
.
next >
Subject
22
Humans
18
Leukemia, Myelogenous, Chronic, B...
16
Pyrimidines
11
Imatinib Mesylate
11
Protein Kinase Inhibitors
10
Antineoplastic Agents
10
Piperazines
9
Benzamides
9
Female
9
Male
.
next >
Date issued
3
2018
6
2017
4
2016
2
2015
2
2014
10
2013
3
2012
4
2011
7
2010